|Videos|August 26, 2021
5-Year Follow-Up Data For CPX-351 in AML
Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
5